28 days
Time to First Decision

Medicines, Volume 9, Issue 8

2022 August - 4 articles

Cover Story: Every three seconds, someone in the world develops Alzheimer’s Disease (AD), which is the most common form of dementia. With over 50 million AD patients worldwide, AD’s progressive memory loss often occurs over a 4–5-year period. There is currently no effective treatment to stop, delay, or prevent AD. The paper by Arendash and colleagues in this volume presents evidence that a new bioengineering technology—Transcranial Electromagnetic Treatment (TEMT)—can stop the cognitive decline of AD for at least 2½ years through daily in-home treatments by caregivers. The cover figure shows a computer simulation of electric fields in the human head with one of the eight TEMT emitters (above the left ear) being ON. Rapid sequential emitter activation provides full brain treatment. View this paper

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (4)

Select all

Case Report

1 Citations

4,998 Views

7 Pages

Ashi Scalp Acupuncture in the Treatment of Secondary Trigeminal Neuralgia Induced by Multiple Sclerosis: A Case Report

Qiong Schürer,
Hamdy Shaban,
Andreas R. Gantenbein,
Giada Todeschini and
Saroj K. Pradhan

Medicines2022, 9(8), 44;https://doi.org/10.3390/medicines9080044

12 August 2022

Background: Multiple sclerosis (MS) is an autoimmune, chronic, inflammatory, demyelinating, and axonal degeneration disease of the central nervous system. Trigeminal neuralgia (TN), a neuropathic facial paroxysmal pain, is prevalent among MS patients...

Full Article

Review

10 Citations

4,963 Views

35 Pages

Rare Heterogeneous Adverse Events Associated with mRNA-Based COVID-19 Vaccines: A Systematic Review

Rana I. Oueijan,
Olivia R. Hill,
Peter D. Ahiawodzi,
Pius S. Fasinu and
Dorothea K. Thompson

Medicines2022, 9(8), 43;https://doi.org/10.3390/medicines9080043

11 August 2022

Background: Since the successful development, approval, and administration of vaccines against SARS-CoV-2, the causative agent of COVID-19, there have been reports in the published literature, passive surveillance systems, and other pharmacovigilance...

Full Article

Article

16 Citations

4,847 Views

25 Pages

Transcranial Electromagnetic Treatment Stops Alzheimer’s Disease Cognitive Decline over a 2½-Year Period: A Pilot Study

Gary Arendash,
Haitham Abulaban,
Susan Steen,
Ross Andel,
Yanhong Wang,
Yun Bai,
Rob Baranowski,
Jon McGarity,
Lyle Scritsmier and
Chuanhai Cao
+ 4 authors

Medicines2022, 9(8), 42;https://doi.org/10.3390/medicines9080042

3 August 2022

Background: There is currently no therapeutic that can stop or reverse the progressive memory impairment of Alzheimer’s disease (AD). However, we recently published that 2 months of daily, in-home transcranial electromagnetic treatment (TEMT) r...

Full Article

Review

7 Citations

7,917 Views

12 Pages

Clinical Perspectives and Management of Edema in Chronic Venous Disease—What about Ruscus?

Imre Bihari,
Jean-Jérôme Guex,
Arkadiusz Jawien and
Gyozo Szolnoky

Medicines2022, 9(8), 41;https://doi.org/10.3390/medicines9080041

25 July 2022

Background: Edema is highly prevalent in patients with cardiovascular disease and is associated with various underlying pathologic conditions, making it challenging for physicians to diagnose and manage. Methods: We report on presentations from a vir...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Medicines - ISSN 2305-6320

Imprint

Download Flyer